Short-term carcinogenicity study of N-methyl-N-nitrosourea in FVB-Trp53 heterozygous mice
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0280214 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Na-Won Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Animal Medicine, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Thymus Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Food and Drug Safety in 2019.
Abstract (Originalsprache)
Carcinogenicity tests predict the tumorigenic potential of various substances in the human body by studying tumor induction in experimental animals. There is a need for studies that explore the use of FVB/N-Trp53 em2Hwl /Korl (FVB-Trp53 +/- ) mice, created by TALEN-mediated gene targeting in Korea, in carcinogenicity tests. This study was performed to determine whether FVB-Trp53 +/- mice are a suitable model for short-term carcinogenicity studies. To compare the carcinogenicity at different concentrations, 25, 50, and 75 mg/kg of N-methyl-N-nitrosourea (MNU), a known carcinogen, were administered intraperitoneally to FVB-Trp53 +/- and wild-type male mice. After 26 weeks, the survival rate was significantly reduced in FVB-Trp53 +/- mice compared to the wild-type mice in the 50 and 75 mg/kg groups. The incidence of thymic malignant lymphoma (TML) in the 50 and 75 mg/kg groups was 54.2 and 59.1% in FVB-Trp53 +/- male mice, respectively. TML metastasized to the lungs, spleen, lymph nodes, liver, kidney, and heart in FVB-Trp53 +/- male mice. Furthermore, the incidence of primary lung tumors, such as adenomas and adenocarcinomas, was 65.4, 62.5, and 45.4% in the FVB-Trp53 +/- mice of the 25, 50, and 75 mg/kg groups, respectively. The main tumor types in FVB-Trp53 +/- mice were TML and primary lung tumors, regardless of the dose of MNU administered. These results suggest that systemic tumors may result from malfunctions in the p53 gene and pathway, which is an important factor in the pathogenesis of human cancers. Therefore, FVB-Trp53 heterozygous mice are suitable for short-term carcinogenicity tests using positive carcinogens, and that the best result using MNU, a positive carcinogen, might have a single dose of 50 mg/kg.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Animal Medicine, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea.
- Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, Republic of Korea.
- Graduate School of Translational Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Sun-Min Seo, Han-Woong Lee, Yang-Kyu Choi
Förderung
- Ministry of Food and Drug Safety in 2019
Zitieren
APA
Kim, N. W., Seo, S. M., Yoo, E. S., Kang, A. R., Lee, J. H., Lee, J. H., Kang, B. C., Lee, H. W., & Choi, Y. K. (2023). Short-term carcinogenicity study of N-methyl-N-nitrosourea in FVB-Trp53 heterozygous mice. PLOS ONE. https://doi.org/10.1371/journal.pone.0280214
Vancouver
Kim NW, Seo SM, Yoo ES, Kang AR, Lee JH, Lee JH, et al. Short-term carcinogenicity study of N-methyl-N-nitrosourea in FVB-Trp53 heterozygous mice. PLOS ONE. 2023. doi:10.1371/journal.pone.0280214
BibTeX
@article{Kim2023,
author = {Kim, Na-Won and Seo, Sun-Min and Yoo, Eun-Seon and Kang, Ah-Reum and Lee, Ji-Hun and Lee, Jae-Hoon and Kang, Byeong-Cheol and Lee, Han-Woong and Choi, Yang-Kyu},
title = {Short-term carcinogenicity study of N-methyl-N-nitrosourea in FVB-Trp53 heterozygous mice},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0280214}
}
EUVIMED